Navigation Links
Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma
Date:9/16/2009

DENVER, Colorado and JERUSALEM, September 16 /PRNewswire/ -- Children's Hospital of Colorado and the Gamida Cell-Teva Joint Venture announced today that Children's Hospital is enrolling patients for the ExCell study. Children's Hospital is the 24th in a series of cord blood transplant sites worldwide, five of which are children's centers, participating in the study in the U.S., Spain, Italy, Hungary and Israel. The trial is researching the safety and efficacy of StemEx as a therapeutic treatment for patients with blood cancers like leukemia and lymphoma.

StemEx is a graft of blood-forming stem/progenitor cells, derived from a single unit of umbilical cord blood and expanded in culture. The graft is composed of non-embryonic stem cells committed to blood formation. The StemEx product is transplanted in combination with non-expanded cells from the same unit. StemEx is being developed by a Joint Venture of Gamida Cell and Teva Pharmaceutical Industries (NASDAQ: TEVA).

"ExCell is an important trial that gives us an opportunity to investigate alternative treatments for blood cancers. We also think it is important that the medical and patient communities are aware of the existence of this trial. Naturally, our team is available for consultation should a referring physician believe this could be the appropriate next step for a patient with leukemia or lymphoma," said Roger Giller MD, principal investigator at The Children's Hospital in Denver, Colorado.

Currently, bone marrow transplantation serves as a life-saving treatment for many types of leukemia and lymphoma. According to the National Marrow Donor Program (NMDP) 70% of patients are unable to find a matched donor in their family but are able to turn to international bone marrow transplant registries to search for an unrela
'/>"/>

SOURCE Gamida Cell LTD
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
2. The MedZilla Report for August 2009 -- Health Care Grows Another 28,000 While Hospitals And Insurers Feel Painful Pinch
3. Childrens Hospital Oakland Standardizes to Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Technology
4. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing
5. SmartGenes Services for Faster, More Precise Identification of Bacteria and Fungi to be Used by The Johns Hopkins Hospital
6. St. Johns Hospital Acquires Latest Technology in Robotic-Assisted Surgery
7. BioNeutrals Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing.
8. Quantros ACE Helps East Jefferson General Hospital Achieve Best-in-Class Performance
9. USC Hospitals Extend Relationship With Quantros to Manage Compliance and Risk
10. BioNeutrals Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms
11. Stem Cell Cord Blood Banking Is Huge Global Business for Hospitals, Says CEO of Bio-Matrix Scientific Group Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , ... August 31, 2015 , ... ... a high priority in the drug development approval process. Thus, innovator companies must ... year, Regis Technologies, Inc., a Chicago-based CMO, has been hosting multiple educational panels ...
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/zsgg5n/global_and_usa ... & USA BioSimilar Market Analysis to 2021" report ... Biosimilar market will be initiated in September as Sandoz ... the global market react? Will biosimilars explode into the ... the US economy up to $250 billion within the ...
(Date:8/28/2015)... ... August 28, 2015 , ... Riordan-McKenna Institute founders, ... today that the use of sterile, dehydrated amniotic tissue AlphaPATCHâ„¢ developed by ... non-healing surgical knee wound. , The case involved a 78-year-old male, who presented ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - Portage Biotech ... PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), ... Phase I study of BHV-0223, a glutamate modulating ... regarding BHV-0223 and recently obtained clearance from the ... with human testing. Portage holds 54% equity interest ...
Breaking Biology Technology:Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
... DIEGO, Feb. 26 Bio-Matrix Scientific Group, Inc. ... today that the San Diego-based biotechnology company is ... Pick" on WallStreetCorner.com ( http://wallstreetcorner.com/stockpick.html ), an editorial ... and Special Situation profiles are regularly read by ...
... for Biomedical,Research today presented its strategies for drug ... A large computational,project with basic research support and ... under the broad-based Epistemic Drug,Discovery(R) project. , ... Institute, Dr. J.R. Prous, explained that "We,are committed ...
... February 26 ScreenCancer AS, a Norwegian,company ... insurance,companies and individuals, today announced that it ... screening test to its European Cancer,Screening Program. ... a subsidiary of Quest Diagnostics Incorporated (NYSE: ...
Cached Biology Technology:Bio-Matrix Scientific Group Featured as 'Stock Pick' in Oakley's Column on WallStreetCorner.com 2Prous Institute Presents Innovative Approach to Drug Discovery 2ScreenCancer Adds InSure(R) FIT(TM) Colorectal Cancer Screening Test to European Cancer Screening Program 2ScreenCancer Adds InSure(R) FIT(TM) Colorectal Cancer Screening Test to European Cancer Screening Program 3
(Date:8/20/2015)... SANTA CLARA, Calif. , Aug. 20, 2015 ... based company focused on improving the user experience ... voice and vision technologies, today announced that its ... and voice biometric authentication software to be ... Alliance tested TrulySecure for compliance with the FIDO ...
(Date:8/19/2015)... 2015  VOXX International Corporation (Nasdaq: VOXX ... a Definitive Agreement to purchase the assets, inclusive ... leader EyeLock through an acquiring entity.  Upon consummation ... interest in the acquiring entity. The closing of ... diligence.  Expanding on its existing supply chain and ...
(Date:8/18/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ... "Global Biometric Authentication & Identification Market: Focus On ... 2015-2020" report to their offering. ... market is expected to grow at an estimated ... generate over $25 billion (approximately) by 2020 as ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
... on a tree trunk always points north. According to new ... also provide a new "compass" for stem cell research, telling ... Dr. Nir Ohad of Tel Aviv University,s ... University of Freiburg have discovered a new use for the ...
... the sea but the medaka knows what it likes. A new ... shows how a single gene mutation that turns Japanese Killifish a ... members of the opposite sex. The medaka, ... range of colours; from brown, to more uncommon orange and grey ...
... of family medicine at SUNY Downstate Medical Center in Brooklyn, ... European Association for the Study of Diabetes (EASD) on October ... October 2 in Vienna, Austria. Dr. Feinman will ... Dietary Strategies in the Treatment of Diabetes. According ...
Cached Biology News:Telltale moss 2Fish go mad for ginger gene 2
The F40 piston assembly is supplied as two assemblies to service one F40 pump of a BioLogic DuoFlow workstation....
... an internal standard for the quantification of ... 5-OxoETE is a polyunsaturated keto acid formed ... neutrophils. It stimulates cytosolic calcium levels in ... 5-OxoETE selectively stimulates the migration and degranulation ...
...
... an internal standard for the quantification of ... 5-OxoETE is a polyunsaturated keto acid formed ... neutrophils. It stimulates cytosolic calcium levels in ... 5-OxoETE selectively stimulates the migration and degranulation ...
Biology Products: